Literature DB >> 8619408

Improvement of erythropoiesis during treatment with deferiprone in a patient with myelofibrosis and transfusional hemosiderosis.

M E Smeets, G Vreugdenhil, R S Holdrinet.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8619408     DOI： 10.1002/(SICI)1096-8652(199603)51:3<243::AID-AJH12>3.0.CO;2-H

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  13 in total

1.  Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging.

Authors:  Emanuela Messa; Sonia Carturan; Chiara Maffè; Marisa Pautasso; Enrico Bracco; Antonella Roetto; Francesca Messa; Francesca Arruga; Ilaria Defilippi; Valentina Rosso; Chiara Zanone; Antonia Rotolo; Elisabetta Greco; Rosa M Pellegrino; Daniele Alberti; Giuseppe Saglio; Daniela Cilloni
Journal:  Haematologica       Date:  2010-06-09       Impact factor: 9.941

Review 2.  Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.

Authors:  Heather A Leitch
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

3.  A case of transfusion independence in a patient with myelodysplastic syndrome using deferasirox, sustained for two years after stopping therapy.

Authors:  D Sanford; C C Hsia
Journal:  Curr Oncol       Date:  2015-04       Impact factor: 3.677

4.  Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes.

Authors:  Norbert Gattermann; Carlo Finelli; Matteo Della Porta; Pierre Fenaux; Michael Stadler; Agnes Guerci-Bresler; Mathias Schmid; Kerry Taylor; Dominique Vassilieff; Dany Habr; Andrea Marcellari; Bernard Roubert; Christian Rose
Journal:  Haematologica       Date:  2012-03-14       Impact factor: 9.941

5.  Iron chelation therapy in myelodysplastic syndromes.

Authors:  Emanuela Messa; Daniela Cilloni; Giuseppe Saglio
Journal:  Adv Hematol       Date:  2010-06-20

6.  Red blood cell transfusion independence following the initiation of iron chelation therapy in myelodysplastic syndrome.

Authors:  Maha A Badawi; Linda M Vickars; Jocelyn M Chase; Heather A Leitch
Journal:  Adv Hematol       Date:  2010-03-23

Review 7.  Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.

Authors:  Christina N Kontoghiorghe; George J Kontoghiorghes
Journal:  Drug Des Devel Ther       Date:  2016-01-29       Impact factor: 4.162

8.  Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670).

Authors:  Anna Angela Di Tucci; Roberta Murru; Daniele Alberti; Bertrand Rabault; Simona Deplano; Emanuele Angelucci
Journal:  Eur J Haematol       Date:  2007-03-28       Impact factor: 2.997

9.  Durable Red Blood Cell Transfusion Independence in a Patient with an MDS/MPN Overlap Syndrome Following Discontinuation of Iron Chelation Therapy.

Authors:  Harpreet Kochhar; Chantal S Leger; Heather A Leitch
Journal:  Case Rep Hematol       Date:  2015-03-30

10.  Mayor erythropoietic response after deferasirox treatment in a transfusion-dependent anemic patient with primary myelofibrosis.

Authors:  Del Corso Lisette; Balleari Enrico; Arboscello Eleonora; Ghio Riccardo; Mencoboni Manlio; Racchi Omar
Journal:  Case Rep Hematol       Date:  2013-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.